Could a breast cancer drug tame kaposi sarcoma?

NCT ID NCT04941274

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called abemaciclib, already used for breast cancer, in people with Kaposi sarcoma (KS), both with and without HIV. The goal is to find a safe dose and see if it can shrink KS tumors. About 111 adults will take the drug daily in 28-day cycles until their cancer worsens or side effects become too much.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abemaciclib (a cancer drug taken as tablets)
What this could lead to: If it works, this could offer a new treatment option for Kaposi sarcoma, potentially shrinking tumors and controlling the disease.
What could go wrong: This is an early-phase trial (phase I/II) with only 111 participants, so the drug may not work or may have side effects. It is not a cure, and patients may need ongoing treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS Kaposi's sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KAPOSI SARCOMA

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.